We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Cenix Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery
News

Cenix Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery

Cenix Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery
News

Cenix Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Cenix Signs Research Agreement with Boehringer Ingelheim for RNAi-Based Target Discovery"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Cenix BioScience GmbH has announced that it has signed a research agreement to support Boehringer Ingelheim in its ongoing efforts to discover novel therapeutic drug targets. Cenix will apply its well-established expertise in combining high throughput (HT) applications of RNAi-based gene silencing, the technology behind the 2006 Nobel Prize for Medicine, with high content phenotypic analyses in what will be a genome-scale screen using cultured human cells. Multi-parametric microscopy-based assays developed by Cenix using the Cellenger image analysis platform from Munich-based Definiens, will be used to complement proprietary assays developed at Boehringer Ingelheim, in order to generate detailed insights into the cellular functions and loss-of-function phenotypes of analyzed genes. “We have long been looking forward to this opportunity to combine our own capabilities with those of our expert colleagues at Boehringer Ingelheim,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We expect that the excellent complementarities between the two teams will deliver a particularly productive and cost-effective driver for these programs.” Such RNAi datasets, now widely favored throughout the industry, offer a highly predictive and cost-effective basis for mining the human genome to discover and prioritize targets for therapeutic drug development in a wide range of disease fields.
Advertisement